Cardiac Sarcoidosis: When and How to Treat Inflammation

Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.

[1]  D. Okada,et al.  Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience. , 2020, Journal of cardiac failure.

[2]  C. Torp‐Pedersen,et al.  Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. , 2020, Journal of the American College of Cardiology.

[3]  S. Kalbfleisch,et al.  High-dose intravenous glucocorticoids are effective in the acute management of ventricular arrhythmias in cardiac sarcoidosis: A case series , 2020, HeartRhythm case reports.

[4]  S. Priori,et al.  Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy , 2020, Circulation.

[5]  T. Aune,et al.  Methotrexate and its mechanisms of action in inflammatory arthritis , 2020, Nature Reviews Rheumatology.

[6]  R. Brunken,et al.  Infliximab for Refractory Cardiac Sarcoidosis. , 2019, The American journal of cardiology.

[7]  L. Gula,et al.  Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). , 2019, American heart journal.

[8]  S. Furuya,et al.  The rate of myocardial perfusion recovery after steroid therapy and its implication for cardiac events in cardiac sarcoidosis and primarily preserved left ventricular ejection fraction , 2019, Journal of Nuclear Cardiology.

[9]  H. Miettinen,et al.  Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. , 2019, European heart journal.

[10]  Corrigendum to: 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  P. Taylor,et al.  How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy , 2019, Journal of clinical medicine.

[12]  L. Cooper,et al.  Management and outcomes of cardiac sarcoidosis: a 20‐year experience in two tertiary care centres , 2018, European journal of heart failure.

[13]  J. Humphreys,et al.  The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis , 2018, Rheumatology.

[14]  H. Miettinen,et al.  Outcome of Cardiac Sarcoidosis Presenting With High-Grade Atrioventricular Block , 2018, Circulation. Arrhythmia and electrophysiology.

[15]  D. Okada,et al.  Isolated cardiac sarcoidosis: A focused review of an under-recognized entity , 2018, Journal of Nuclear Cardiology.

[16]  D. Maucort-Boulch,et al.  Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. , 2017, Seminars in arthritis and rheumatism.

[17]  L. Cooper,et al.  Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring , 2017, Journal of Nuclear Cardiology.

[18]  M. Cerqueira,et al.  Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18F-FDG PET Scans for Suspected Cardiac Sarcoidosis. , 2017, JACC. Cardiovascular imaging.

[19]  C. Narasimhan,et al.  Tailored approach for management of ventricular tachycardia in cardiac sarcoidosis , 2017, Journal of cardiovascular electrophysiology.

[20]  Amit R. Patel,et al.  Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis. , 2017, JACC. Cardiovascular imaging.

[21]  R. Blankstein,et al.  Presence of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Among Patients With Suspected Cardiac Sarcoidosis Is Associated With Adverse Cardiovascular Prognosis: A Systematic Review and Meta-Analysis , 2016, Circulation. Cardiovascular imaging.

[22]  B. Ky,et al.  Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. , 2016, Circulation.

[23]  M. Hiroe,et al.  Steroid pulse therapy was effective for cardiac sarcoidosis with ventricular tachycardia and systolic dysfunction , 2016, ESC heart failure.

[24]  R. Baughman,et al.  Biologic therapies in the treatment of sarcoidosis , 2016, Expert review of clinical immunology.

[25]  Amit R. Patel,et al.  Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction , 2016, Circulation. Cardiovascular imaging.

[26]  T. Akasaka,et al.  Comparison of cardiac MRI and 18F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complet heart block. , 2015, Heart rhythm.

[27]  T. Aiba,et al.  Effect of Corticosteroid Therapy on Long-Term Clinical Outcome and Left Ventricular Function in Patients With Cardiac Sarcoidosis. , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[28]  J. Airaksinen,et al.  Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. , 2015, Circulation.

[29]  Hiroshi Ito,et al.  Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. , 2015, The American journal of cardiology.

[30]  C. Albert,et al.  Ventricular Tachycardia in Cardiac Sarcoidosis: Characterization of Ventricular Substrate and Outcomes of Catheter Ablation , 2015, Circulation. Arrhythmia and electrophysiology.

[31]  Amit R. Patel,et al.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. , 2014, Heart rhythm.

[32]  A. Prasse,et al.  Sarcoidosis , 2014, The Lancet.

[33]  R. Blankstein,et al.  Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis , 2014, Journal of Nuclear Cardiology.

[34]  J. Garcia,et al.  Rituximab in the treatment of refractory pulmonary sarcoidosis , 2014, European Respiratory Journal.

[35]  Jia Liu,et al.  Imbalance between Th17 and Regulatory T-Cells in Sarcoidosis , 2013, International journal of molecular sciences.

[36]  P. Nery,et al.  Corticosteroid therapy for cardiac sarcoidosis: a systematic review. , 2013, The Canadian journal of cardiology.

[37]  G. Wells,et al.  Is There an Association Between Clinical Presentation and the Location and Extent of Myocardial Involvement of Cardiac Sarcoidosis as Assessed by 18F- Fluorodoexyglucose Positron Emission Tomography? , 2013, Circulation. Cardiovascular imaging.

[38]  A. Bast,et al.  Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide , 2013, Current opinion in pulmonary medicine.

[39]  A. Barton,et al.  The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases , 2013, Rheumatology.

[40]  W. Drake,et al.  Reversal of Global CD4+ Subset Dysfunction Is Associated with Spontaneous Clinical Resolution of Pulmonary Sarcoidosis , 2013, The Journal of Immunology.

[41]  Jon Hainer,et al.  Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. , 2012, Journal of the American College of Cardiology.

[42]  K. Yodogawa,et al.  Effect of Corticosteroid Therapy on Ventricular Arrhythmias in Patients with Cardiac Sarcoidosis , 2011, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[43]  Daniel A Culver,et al.  A concise review of pulmonary sarcoidosis. , 2011, American journal of respiratory and critical care medicine.

[44]  M. Judson,et al.  Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. , 2010, Respiratory medicine.

[45]  C. Bombardier,et al.  Published Online First , 2008 .

[46]  G. Raghu,et al.  Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial , 2008, European Respiratory Journal.

[47]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[48]  R. D. du Bois,et al.  Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. , 2006, American journal of respiratory and critical care medicine.

[49]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[50]  M. Isobe,et al.  Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. , 2001, The American journal of cardiology.

[51]  D. Kemeny,et al.  Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung , 1997, Clinical and experimental immunology.

[52]  R. Baughman,et al.  Prolonged use of methotrexate for sarcoidosis. , 1995, Archives of internal medicine.

[53]  Y. Kawabata,et al.  Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern , 1993, Acta pathologica japonica.

[54]  D. Okada,et al.  Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis , 2018, Circulation. Cardiovascular imaging.

[55]  R. Gorodkin,et al.  BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. , 2017, Rheumatology.

[56]  L. Cooper,et al.  Successful use of rituximab in refractory cardiac sarcoidosis. , 2016, Rheumatology.

[57]  A. Ha,et al.  Cardiac Sarcoidosis. , 2016, Journal of the American College of Cardiology.

[58]  S. Nagai,et al.  Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. , 2014, Internal medicine.

[59]  F. Wamboldt,et al.  Management of cardiac sarcoidosis in the United States: a Delphi study. , 2012, Chest.

[60]  S. Nakatani,et al.  Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. , 2005, The American journal of cardiology.